(a) General requirements. The applicant must comply with the requirements of §§ 314.70 and 314.71 regarding the submission of supplemental ANDAs and other changes to an approved ANDA.
(b) Different listed drug. An applicant may not supplement an ANDA to seek approval of a drug referring to a listed drug that is different from the current reference listed drug identified in the ANDA. This paragraph (b) applies if changes are proposed in a supplement to the ANDA such that the proposed product is a pharmaceutical equivalent to a different listed drug than the reference listed drug identified in the ANDA. A change of reference listed drug must be submitted in a new ANDA. However, notwithstanding the limitation described in this paragraph (b), an applicant may supplement the ANDA to seek approval of a different strength.
[81 FR 69653, Oct. 6, 2016]
Notes of Decisions
Bartlett v. MUTUAL PHARMACEUTICAL CO., INC. (2009)
nhd · cites it 4×
“at 17987 (codified at 21 C.F.R. § 314.97 ). 5. Generic manufacturers’ reporting obligations The ANDA regulations promulgated after Hatch-Waxman require that “each applicant having an [ANDA] .”
Mensing v. Wyeth, Inc. (2009)
ca8 · cites it 2×
“Yet, 21 C.F.R. § 314.97 compels generic manufacturers to “comply with the requirements of § []314.”
Demahy v. Wyeth Inc. (2008)
laed · cites it 5×
“Finally, this excerpt from § N of the 1989 Proposed Rule sheds light on the meaning of 21 C.F.R. § 314.97 (discussed in further detail below in section C(3)).”
Demahy v. Actavis, Inc. (2010)
ca5 · cites it 2×
“On the other hand, what the FDA clearly did do to implement Hatch-Waxman cuts against Actavis’s position, or at the very least muddies congressional and agency intent: it promulgated 21 C.F.R. § 314.97 , entitled “Supplements and other changes to an approved abbreviated…”
Dorsett v. Sandoz, Inc. (2010)
cacd · cites it 3×
“70 (concerning supplements and other changes to an approved application); 21 C.F.R. § 314.97 (applying §§ 314.70 and 314.”
Gaeta v. Perrigo Pharmaceuticals Co. (2011)
ca9 · cites it 2×
“70 is expressly made applicable to ANDA holders by operation of 21 C.F.R. § 314.97 , which is located in Subpart C of the Regulations (entitled, “Abbreviated Applications”) and provides that ANDA applicants “shall comply with the requirements of §§ 314.”
Morris v. Wyeth, Inc. (2009)
kywd · cites it 2×
“150 , and based on its understanding of 21 C.F.R. § 314.97 . The Demahy court reasoned that because the CBE regulation applies to ANDA holders, generic drug manufacturers have the ability to unilaterally change their labels to conform to heightened state warnings.”
Stacel v. Teva Pharmaceuticals, USA (2009)
ilnd
“But 21 C.F.R. § 314.97 is not silent — it states that generic drug manufacturers are obligated to comply with the same CBE provisions as brand-listed manufacturers are.”
VITATOE v. Mylan Pharmaceuticals, Inc. (2010)
wvnd · cites it 2×
“The circuit court’s analysis noted that the contention of the generic drug manufacturers, that they were prohibited from using the CBE process to modify or alter drug labels without FDA approval, was in direct conflict with 21 C.F.R. § 314.97 , which requires them to “ ‘comply…”
Fulgenzi v. Wyeth, Inc. (2010)
ohnd
“Because of this requirement, the generic drug manufacturers, like generic manufacturers in the present case, argued that they were prohibited from implementing a unilateral change without FDA approval.”
Kellogg v. Wyeth (2009)
vtd
“As this Court wrote in its earlier opinion, 21 C.F.R. § 314.97 requires an ANDA applicant to comply with the requirements of §§ 314.”
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.